Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/24
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/24
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/25/24
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor ConferenceGlobeNewsWire • 10/23/24
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and OlderGlobeNewsWire • 10/18/24
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin TypesGlobeNewsWire • 09/25/24
FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverGlobeNewsWire • 09/24/24
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks LikelySeeking Alpha • 08/22/24
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/22/24
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/15/24
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/14/24
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.GlobeNewsWire • 07/29/24
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic DermatitisGlobeNewsWire • 07/29/24
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of AgeGlobeNewsWire • 07/09/24
Cheap Stocks To Buy: Is It Time To Buy This Ship Transport Leader?Investors Business Daily • 06/26/24
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a BetZacks Investment Research • 06/14/24